CD4 and glioblastoma: At the mRNA level, CXCR4 expression positively correlated with B cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells and negatively correlated with CD8+ T cells (Figure 7B), implying that CXCR4 has excellent potential for evaluating GBM immunotherapies [23,24].